Stroke prevention in atrial fibrillation patients

Bibliography

• Go AS, Hylek EM, Phillips KA, Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370-5
   PubMed Web of Science ®Google Scholar
• Miyasaka Y, Barnes ME, Gersh BJ, Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence [published correction appears in Circulation. 2006;114:e498]. Circulation 2006;114:119-25
   PubMed Web of Science ®Google Scholar
• Lloyd-Jones DM, Wang TJ, Leip EP, Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 2004;110:1042-6
   PubMed Web of Science ®Google Scholar
• Feinberg WM, Blackshear JL, Laupacis A, Prevalence, age distribution, and gender of patients with atrial fibrillation. Arch Intern Med 1995;155:469-73
   PubMed Web of Science ®Google Scholar
• Jahangir A, Lee V, Friedman PA, Long-term progression and outcomes with aging in patients with lone atrial fibrillation. A 30-year follow-up study. Circulation 2007;115:3050-6
   PubMed Web of Science ®Google Scholar
• Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983-8
   PubMed Web of Science ®Google Scholar
• Benjamin EJ, Levy D, Vaziri SM, Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994;271:840-4
   PubMed Web of Science ®Google Scholar
• Fuster V, Ryden LE, Cannom DS, ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to revise the 2001 Guidelines for the Management of Patients with atrial fibrillation). J Am Coll Cardiol 2006;48:e149-6
   Web of Science ®Google Scholar
• Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154:1449-57
   PubMed Web of Science ®Google Scholar
• Wattigney WA, Mensah GA, Croft JB. Increasing trends in hospitalisation for atrial fibrillation in the United States, 1985 through 1999: implications for primary prevention. Circulation 2003;108:711-16
   PubMed Web of Science ®Google Scholar
• Stewart S, MacIntyre K, MacLeod MMC, Trends in hospital activity, morbidity and case fatality related to atrial fibrillation in Scotland, 1986 – 1996. Eur Heart J 2001;22:693-701
   PubMed Web of Science ®Google Scholar
• Wolf PA, Benjamin EJ, Belanger AJ, Secular trends in the prevalence of atrial fibrillation: the Framingham Study. Am Heart J 1996;131:790-5
   PubMed Web of Science ®Google Scholar
• Leonardi M, Bissett J. Prevention of atrial fibrillation. Curr Opin Cardiol 2005;20:417-23
   PubMed Web of Science ®Google Scholar
• Watson T, Arya A, Sulke N, Lip GYH. Relationship of indices of inflammation and thrombogenesis to arrhythmia burden in paroxysmal atrial fibrillation. Chest 2009; doi:10.1378/chest.09-1426
   Google Scholar
• Page RL, Tilsch TW, Connolly SJ, ; Azimilide Supraventricular Arrhythmia Program (ASAP) Investigators. Asymptomatic or ‘silent’ atrial fibrillation: frequency in untreated patients and patients receiving azimilide. Circulation 2003;107:1141-5
   PubMed Web of Science ®Google Scholar
• Hohnloser SH, Pajitnev D, Pogue J, ACTIVE W Investigators. Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy. An ACTIVE W substudy. J Am Coll Cardiol 2007;50:2156-61
   PubMed Web of Science ®Google Scholar
• Postma AV, Dekker LR, Soufan AT, Moorman AF. Developmental and genetic aspects of atrial fibrillation. Trends Cardiovasc Med 2009;19:123-30
   PubMed Web of Science ®Google Scholar
• Valderrábano M. Atrial fibrillation: the mother rotor and its rebellious offspring take turns sustaining the family. Heart Rhythm 2009;6:1018-19
   Google Scholar
• Nattel S. Basic electrophysiology of the pulmonary veins and their role in atrial fibrillation: precipitators, perpetuators, and perplexers. J Cardiovasc Electrophysiol 2003;14:1372-5
   Google Scholar
• Fox CS, Parise H, D'Agostino RB Sr, Parental atrial fibrillation as a risk factor for atrial fibrillation in offspring. JAMA 2004;291:2851-5
   PubMed Web of Science ®Google Scholar
• Aguilar MI, Hart R, Pearce LA. Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks [Review]. Stroke 2008;39:1399-400
   Web of Science ®Google Scholar
• Stroke Risk in Atrial Fibrillation Working Group. Comparison of 12 risk stratification schemes to predict stroke in patients with nonvalvular atrial fibrillation. Stroke 2008;39:1901-10
   PubMed Web of Science ®Google Scholar
• Fatkin D, Kelly RP, Feneley MP. Relations between left atrial appendage blood flow velocity, spontaneous echocardiographic contrast and thromboembolic risk in vivo. J Am Coll Cardiol 1994;23:961-9
   PubMed Web of Science ®Google Scholar
• Lip GY. Does atrial fibrillation confer a hypercoagulable state? Lancet 1995;346:1313-14
   PubMed Web of Science ®Google Scholar
• Boos CJ, Anderson RA, Lip GY. Is atrial fibrillation an inflammatory disorder? Eur Heart J 2006;27:136-49
   PubMed Web of Science ®Google Scholar
• Watanabe T, Takeishi Y, Hirono O, C-reactive protein elevation predicts the occurrence of atrial structural remodeling in patients with paroxysmal atrial fibrillation. Heart Vessels 2005;20:45-9
   PubMed Web of Science ®Google Scholar
• Neumann FJ, Ott I, Marx N, Effect of human recombinant interleukin-6 and interleukin-8 on monocyte procoagulant activity. Arterioscler Thromb Vasc Biol 1997;17:3399-405
   PubMed Web of Science ®Google Scholar
• Marin F, Roldan V, Climent V, Is thrombogenesis in atrial fibrillation related to matrix metalloproteinase-1 and its inhibitor, TIMP-1? Stroke 2005;36:1115-19
   PubMed Web of Science ®Google Scholar
• Whalley GA, Wright SP, Pearl A, Prognostic role of echocardiography and brain natriuretic peptide in symptomatic breathless patients in the community. Eur Heart J 2008;29:509-16
   PubMed Web of Science ®Google Scholar
• van Walraven C, Hart RG, Singer DE, Oral anticoagulants vs. aspirin in nonvalvular atrial fibrillation. An individual patient meta-analysis. JAMA 2002;288:2441-8
   PubMed Web of Science ®Google Scholar
• Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have non-valvular atrial fibrillation. Ann Intern Med 2007;146:857-67
   PubMed Web of Science ®Google Scholar
• Petersen P, Boysen G, Godtfredsen J, Placebo controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet 1989;1:175-9
   PubMed Web of Science ®Google Scholar
• Stroke prevention in atrial fibrillation study. Final results. Circulation 1991;84:527-39
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Laupacis A, Gent M, Canadian atrial fibrillation anticoagulation (CAFA) study. J Am Coll Cardiol 1991;18:349-55
   PubMed Web of Science ®Google Scholar
• EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993;342:1255-62
   PubMed Web of Science ®Google Scholar
• The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990;323:1505-11
   PubMed Web of Science ®Google Scholar
• Ezekowitz MD, Bridgers SL, James KE, ; Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med 1992;327:1406-12
   PubMed Web of Science ®Google Scholar
• Lip GY, Edwards SJ. Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: a systematic review and meta-analysis. Thromb Res 2006;118:321-33
   PubMed Web of Science ®Google Scholar
• Cooper NJ, Sutton AJ, Lu G, Khunti K. Mixed comparison of stroke prevention treatments in individuals with nonrheumatic atrial fibrillation. Arch Intern Med 2006;166:1269-75
   PubMed Web of Science ®Google Scholar
• National Collaborating Centre for Chronic Conditions. Atrial Fibrillation: National Clinical Guideline for Management in Primary and Secondary Care. London: Royal College of Physicians, 2006. Available from: www.nice.org.uk
   Google Scholar
• Singer DE, Dalen JE, Fang MC, Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, 8th edition. Chest 2008;133:S546-92
   PubMed Web of Science ®Google Scholar
• Petersen P, Boysen G. Prevention of stroke in atrial fibrillation. N Engl J Med 1990;323:482
   Google Scholar
• Diener HC, Lowenthal A. Antiplatelet therapy to prevent stroke: risk of brain hemorrhage and efficacy in atrial fibrillation. J Neurol Sci 1997;153:112-13
   Web of Science ®Google Scholar
• Benavente O, Hart R, Koudstaal P, Antiplatelet therapy for preventing stroke in patients with atrial fibrillation and no previous history of stroke or transient ischemic attacks. In: Warlow C, Van Gijn J, Sandercock P, editors. Stroke Module of the Cochrane Database of Systematic Reviews. Cochrane Collaboration, Oxford; 1999
   Google Scholar
• Posada IS, Barriales V.; LASAF Pilot Study Group. Alternate-day dosing of aspirin in atrial fibrillation. Am Heart J 1999;138:137-43
   PubMed Web of Science ®Google Scholar
• Sato H, Ishikawa, Kitabatake A, ; on behalf of the Japan Atrial Fibrillation Stroke Trial (JAST) group. Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial. Stroke 2006;37:447-51
   PubMed Web of Science ®Google Scholar
• Edvardsson N, Juul-Möller S, Omblus R, Pehrsson K. Effects of low-dose warfarin and aspirin versus no treatment on stroke in a medium-risk patient population with atrial fibrillation. J Intern Med 2003;254:95-101
   PubMed Web of Science ®Google Scholar
• Diener HC, Cunha L, Forbes C, European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996;143:1-13
   PubMed Web of Science ®Google Scholar
• Vemmos KN, Tsivgoulis G, Spengos K, Primary prevention of arterial thromboembolism in the oldest old with atrial fibrillation – a randomized pilot trial comparing adjusted-dose and fixed low-dose coumadin with aspirin. Eur J Intern Med 2006;17:48-52
   PubMed Web of Science ®Google Scholar
• Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994;343:687-91
   PubMed Web of Science ®Google Scholar
• Gullov AL, Koefoed BG, Petersen P, Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study. Arch Intern Med 1998;158:1513-21
   PubMed Web of Science ®Google Scholar
• Hellemons BS, Langenberg M, Lodder J, Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomised controlled trial comparing two intensities of coumarin with aspirin. BMJ 1999;319:958-64
   PubMed Web of Science ®Google Scholar
• Antithrombotic Therapy in Atrial Fibrillation Study Group. [The randomized study of efficiency and safety of antithrombotic therapy in nonvalvular atrial fibrillation: warfarin compared with aspirin.] Zhonghua Xin Xue Guan Bing Za Zhi 2006;34:295-8
   PubMedGoogle Scholar
• Rash A, Downes T, Portner R, A randomised controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO). Age Ageing 2007;36:151-6
   PubMed Web of Science ®Google Scholar
• Mant J, Hobbs FDR, Fletcher K, ; BAFTA investigators; Midland Research Practices Network (MidReC). Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomized controlled trial. Lancet 2007;370:493-503
   PubMed Web of Science ®Google Scholar
• Morocutti C, Amabile G, Fattapposta F, Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation. SIFA (Studio Italiano Fibrillazione Atriale) Investigators. Stroke 1997;28:1015-21
   PubMed Web of Science ®Google Scholar
• NASPEAF Investigators. Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: a randomized multicenter study. J Am Coll Cardiol 2004;44:1557-66
   PubMed Web of Science ®Google Scholar
• ACTIVE Writing Group; on behalf of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006;367:1903-12
   PubMed Web of Science ®Google Scholar
• SPAF Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996;348:633-8
   PubMed Web of Science ®Google Scholar
• Fang MC, Go AS, Hylek EM, Age and the risk of warfarin associated hemorrhage: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. J Am Geriatr Soc 2006;54:1231-6
   PubMed Web of Science ®Google Scholar
• Palareti G, Cosmi B. Bleeding with anticoagulation therapy – who is at risk, and how best to identify such patients. Thromb Haemost 2009;102:268-78
   PubMed Web of Science ®Google Scholar
• Hughes M, Lip GY. Guideline Development Group for the NICE national clinical guideline for management of atrial fibrillation in primary and secondary care. Risk factors for anticoagulation-related bleeding complications in patients with atrial fibrillation: a systematic review. QJM 2007;100:599-607
   Google Scholar
• Fang MC, Chen J, Rich MW. Atrial fibrillation in the elderly. Am J Med 2007;120:481-7
   PubMed Web of Science ®Google Scholar
• White HD, Gruber M, Feyzi J, Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med 2007;167:239-45
   PubMed Web of Science ®Google Scholar
• Jones M, Mc Ewan P, Morgan CL, Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with nonvalvular atrial fibrillation: a record linkage study in a large British population. Heart 2005;91:472-7
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Pogue J, Eikelboom J, ; ACTIVE W Investigators. Benefit of oral anticoagulant over antiplatelet therapy in AF depends on the quality of the INR control achieved as measured by time in therapeutic range. Circulation 2008;118:2029-37
   PubMed Web of Science ®Google Scholar
• Morgan CL, McEwan P, Tukiendorf A, Warfarin treatment in patients with atrial fibrillation: observing outcomes associated with varying levels of INR control. Thromb Res 2009;124:37-41
   PubMed Web of Science ®Google Scholar
• Wan Y, Heneghan C, Perera R, Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circ Cardiovasc Qual Outcomes 2008;1:84-91
   PubMed Web of Science ®Google Scholar
• Tay KH, Lane DA, Lip GY. Bleeding risks with combination of oral anticoagulation plus antiplatelet therapy: is clopidogrel any safer than aspirin when combined with warfarin? Thromb Haemost 2008;100:955-7
   PubMed Web of Science ®Google Scholar
• Gage BF, Yan Y, Milligan PE, Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 2006;151:713-19
   PubMed Web of Science ®Google Scholar
• Pisters R, Lane DA, Nieuwlaat R, A novel user-friendly score (HAS-BLED) to assess one-year risk of major bleeding in atrial fibrillation patients: the Euro Heart Survey. Chest 2010. [Epub 18 Mar 2010]
   Google Scholar
• Stroke Risk in Atrial Fibrillation Working Group. Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology 2007;69:546-54
   PubMed Web of Science ®Google Scholar
• Stroke Risk in Atrial Fibrillation Working Group. Comparison of 12 risk stratification schemes to predict stroke in patients with nonvalvular atrial fibrillation. Stroke 2008;39:1901-10
   PubMed Web of Science ®Google Scholar
• Albers GW, Dalen JE, Laupacis A, Antithrombotic therapy in atrial fibrillation. Chest 2001;119:194-206S
   PubMed Web of Science ®Google Scholar
• Gage BF, Waterman AD, Shannon W, Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001;285:2864-70
   PubMed Web of Science ®Google Scholar
• Hart RG, Pearce LA, McBride R, Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials: the Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. Stroke 1999;30:1223-9
   PubMed Web of Science ®Google Scholar
• Singer DE, Albers GW, Dalen JE, Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:429-56S
   PubMed Web of Science ®Google Scholar
• van Walraven C, Hart RG, Wells GA, A clinical prediction rule to identify patients with atrial fibrillation and a low risk for stroke while taking aspirin. Arch Intern Med 2003;163:936-43
   PubMedGoogle Scholar
• Wang TJ, Massaro JM, Levy D, A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. JAMA 2003;290:1049-56
   PubMed Web of Science ®Google Scholar
• Kopecky SL, Gersh BJ, McGoon MD, The natural history of lone atrial fibrillation. A population-based study over three decades. N Engl J Med 1987;317:669-74
   PubMed Web of Science ®Google Scholar
• Predictors of thromboembolism in atrial fibrillation: I. Clinical features of patients at risk. The Stroke Prevention in Atrial Fibrillation Investigators. Ann Intern Med 1992;116:1-5
   PubMed Web of Science ®Google Scholar
• Go AS, Hylek EM, Phillips KA, ; ATRIA Study Investigators. Implications of stroke risk criteria on the anticoagulation decision in nonvalvular atrial fibrillation. The anticoagulation and risk factors in atrial fibrillation. Circulation 2000;102:11-3
   PubMed Web of Science ®Google Scholar
• Stroke Prevention in Atrial Fibrillation Investigators. Risk factor for thromboembolism during aspirin therapy in patients with atrial fibrillation: the Stroke Prevention in Atrial Fibrillation Study. J Stroke Cerebrovasc Dis 1995;5:147-57
   PubMedGoogle Scholar
• Fang MC, Go AS, Chang Y, ; for the ATRIA Study Group. Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation. J Am Coll Cardiol 2008;51:810-15
   PubMed Web of Science ®Google Scholar
• Baruch L, Gage BF, Horrow J, Can patients at elevated risk of stroke treated with anticoagulants be further risk stratified? Stroke 2007;38:2459-63
   PubMed Web of Science ®Google Scholar
• Lip GYH, Nieuwlaat R, Pisters R, Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor based approach: the Euro Heart Survey on Atrial Fibrillation. Chest 2010;137:263-72
   Google Scholar
• Lip GYH, Lim HS. Atrial fibrillation and stroke prevention. Lancet Neurol 2007;6:981-93
   PubMed Web of Science ®Google Scholar
• Olsson SB. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 2003;362:1691-8
   PubMed Web of Science ®Google Scholar
• Albers GW, Diener HC, Frison L, Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA 2005;293:690-8
   PubMed Web of Science ®Google Scholar
• Halperin JL. Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V). Am Heart J 2003;146:431-8
   PubMed Web of Science ®Google Scholar
• Kaul S, Diamond GA, Weintraub WS. Trials and tribulations of non-inferiority: the ximelagatran experience. J Am Coll Cardiol 2005;46:1986-95
   PubMed Web of Science ®Google Scholar
• Boudes PF. The challenges of new drugs benefits and risks analysis: lessons from the ximelagatran FDA Cardiovascular Advisory Committee. Contemp Clin Trials 2006;27:432-40
   PubMed Web of Science ®Google Scholar
• Bousser MG, Bouthier J, Buller HR, ; Amadeus Investigators. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial. Lancet 2008;371:315-21
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, ; the RE-LY Steering Committee and Investigators. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med 2009;361:1139-51
   PubMed Web of Science ®Google Scholar
• Kaul S, Diamond GA. Good enough: a primer on the analysis and interpretation of noninferiority trials. Ann Intern Med 2006;145:62-9
   PubMed Web of Science ®Google Scholar
• Albers GW, Diener HC, Frison L, Trials and tribulations of noninferiority: the ximelagatran experience. J Am Coll Cardiol 2006;48:1058
   PubMed Web of Science ®Google Scholar
• Lip GYH, Lane DA. Myocardial infarction events in contemporary clinical trials of anticoagulation for stroke prevention in atrial fibrillation patients: does warfarin have a protective effect? Am J Med 2010; In press
   Google Scholar
• Khoo CW, Tay KH, Shantsila E, Lip GY. Novel oral anticoagulants. Int J Clin Pract 2009;63:630-41
   PubMed Web of Science ®Google Scholar
• Lip GY, Rasmussen LH, Olsson SB, ; Steering Committee. Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists. Eur Heart J 2009;30:2897-907
   PubMed Web of Science ®Google Scholar
• ROCKET AF Study Investigators. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J 2010;159:340-7
   PubMed Web of Science ®Google Scholar
• Lopes RD, Alexander JH, Al-Khatib SM, ; ARISTOTLE Investigators. Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J 2010;159:331-9
   PubMed Web of Science ®Google Scholar
• Eikelboom JW, O'Donnell M, Yusuf S, Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment. Am Heart J 2010;159:348-53
   PubMed Web of Science ®Google Scholar
• Heneghan C, Alonso-Coello P, Garcia-Alamino JM, Self-monitoring of oral anticoagulation: a systematic review and meta-analysis. Lancet 2006;367:404-11
   PubMed Web of Science ®Google Scholar
• van Walraven C, Jennings A, Oake N, Effect of study setting on anticoagulation control: a systematic review and metaregression. Chest 2006;129:1155-66
   PubMed Web of Science ®Google Scholar
• Rose AJ, Berlowitz DR, Frayne SM, Hylek EM. Measuring quality of oral anticoagulation care: extending quality measurement to a new field. Jt Comm J Qual Patient Saf 2009;35:146-55
   PubMedGoogle Scholar
• Marinigh R, Lip GYH, Lane DA. Age as a risk factor for stroke in atrial fibrillation patients: implications for thromboprophylaxis. J Am Coll Cardiol 2010; In press
   Google Scholar
• The SPAF III Writing Committee for the Stroke Prevention in Atrial fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomsied clinical trial. Lancet 1996;348:633-8
   PubMed Web of Science ®Google Scholar
• Pengo V, Zasso A, Barbero F, Effectiveness of fixed minidose warfarin in the prevention of thromboembolism and vascular death in nonrheumatic atrial fibrillation. Am J Cardiol 1998;82:433-7
   PubMed Web of Science ®Google Scholar
• Farrell B, Godwin J, Richards S; on behalf of the UK-TIA study group. The United-Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 1991;54:1044-54
   PubMed Web of Science ®Google Scholar
• Lechat P, Lardoux H, Mallet A, Anticoagulant (fluindione)-aspirin combination in patients with high-risk atrial fibrillation: a randomized trial (Fluindione, Fibrillation, Auriculaire, Aspirin et Contraste Spontane; FFAACS). Cerebrovasc Dis 2001;12:245-52
   PubMed Web of Science ®Google Scholar
• Hu DY, Zhang HP, Sun YH, Jiang LQ; on behalf of the Antithrombotic Therapy in Atrial Fibrillation Study Group. The randomised study of efficiency and safety of antithrombotic therapy in non-valvular atrial fibrillation: warfarin compared with aspirin. Chin J Cardiol 2006;34:295-8
   Google Scholar
• Connolly SJ, Pogue J, Hart RG, ; ACTIVE Investigators. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009;360:2066-78
   PubMed Web of Science ®Google Scholar
• Healey JS, Hart RG, Pogue J, Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE-W). Stroke 2008;39:1482-6
   PubMed Web of Science ®Google Scholar